A Phase 1 interventional study of Abemaciclib and Darolutamide in Prostatic Neoplasms, sponsored by Eli Lilly and Company. Terminated at 13 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing abemaciclib in Prostatic Neoplasms — 1 open to participants now, 3 under way, 2 of them phase 3. abemaciclib · Prostatic Neoplasms.
Among the 10 studies testing abemaciclib in Prostatic Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2024, is one of 2 in phase 1, and was the 9th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →1 of the 10 studies testing abemaciclib in Prostatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Vadim S Koshkin · Sites in United States
Ages 18+
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 2
First in 2018; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 15 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 7 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
20 studies in Prostatic Neoplasms by Eli Lilly and Company: 2 open now, 8 under way, 3 of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 20 studies in Prostatic Neoplasms by Eli Lilly and Company, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 1, and was the 16th registered.
Eli Lilly and Company’s Prostatic Neoplasms studies by the year they started, since 2007.
1 of the studies testing abemaciclib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05113537Vadim S KoshkinAbemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing abemaciclib in Prostatic Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 20 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with darolutamide to participants with prostate cancer that has spread after initial treatment. Participation may last up to 32 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
castration-resistant prostate cancer evidenced by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abemaciclib plus (+) darolutamide. Participants who have not undergone bilateral orchiectomy are required to continue background androgen deprivation therapy (ADT) with a luteinizing hormone-releasing hormone (LHRH) agonist/antagonist throughout the study.
Drug: Abemaciclib · Drug: Darolutamide · Drug: LHRH agonist/antagonist
Administered orally.
Also known as: LY2835219
Administered orally.
Drug pages: Gonadotropin-releasing Hormone Analog · Antagonist
Physician's choice. Administered in accordance with the prescribing information.
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Administration Number of Participants with One or More SAEs Considered by the Investigator to be Related to Study Drug Administration
Time frame: Date of first dose to study completion (approximately 32 months)
Radiographic Progression-Free Survival (rPFS) Assessed by Investigator rPFS Assessed by Investigator
rPFS Assessed by Investigator
Time frame: Date of first dose to radiographic disease progression or death from any cause (approximately 32 months)
Objective Response Rate (ORR): Percentage of Participants with Soft Tissue Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
ORR: Percentage of Participants with Soft Tissue BOR of CR or PR
Time frame: Date of first dose to radiographic disease progression or death from any cause (approximately 32 months)
Duration of Response (DoR)
DOR
Time frame: Date of first documented CR or PR to radiographic disease progression or death from any cause (approximately 32 months)
Time to Prostate Specific Antigen (PSA) Progression
Time to PSA progression
Time frame: Date of first dose to the first observation of PSA progression (approximately 32 months)
Prostate Specific Antigen (PSA) Response Rate (PSA-RR): Percentage of Participants with a PSA Decrease of at Least 50% from Baseline
PSA-RR
Time frame: Date of first dose to confirmed PSA progression (approximately 32 months)
Pharmacokinetics (PK): Mean Concentrations of Abemaciclib and its Active Metabolite(s)
PK: Mean Concentrations of Abemaciclib and its Active Metabolite(s)
Time frame: Cycle 1 Day 1 until Cycle 2 Day 1 (Cycle = 28 days)
Pharmacokinetics (PK): Mean Concentrations of Darolutamide and its Active Metabolite
PK: Mean Concentrations of Darolutamide and its Active Metabolite
Time frame: Cycle 1 Day 1 until Cycle 2 Day 1 (Cycle = 28 days)
Plan to share: No
Ran from Jan 2024 to primary completion in Feb 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abemaciclib · Darolutamide